Trade names Palladia ATCvet code QL01XE91 (WHO) Protein binding 91%-93% Bioavailability 77% ChEMBL ID 13608 Trade name Palladia | Routes ofadministration Oral Legal status US: ℞-only Molar mass 396.46 g/mol Pubchem 8034466 ChemSpider ID 4486268 | |
![]() | ||
AHFS/Drugs.com International Drug Names |
Toceranib is a receptor tyrosine kinase inhibitor and is used in the treatment of canine mast cell tumor also called mastocytoma. Together with masitinib (Kinavet (US)/Masivet (EU/ROW) by AB Science), toceranib is the only dog-specific anti-cancer drug approved by the U.S. Food and Drug Administration. It is marketed as Palladia as its phosphate salt, toceranib phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.
References
Toceranib Wikipedia(Text) CC BY-SA